The BRCAnalysis® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
BRACAnalysis ® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. BRCA mutations are responsible for the majority of hereditary breast and ovarian cancers. People with a mutation in either the BRCA1 or BRCA2 gene have risks of up to 87 percent for developing breast cancer and 39-63 percent for developing ovarian cancer by age 70. This test assess a person’s risk of developing hereditary breast and ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
How is it carried out?
BRACAnalysis ® requires only a simple blood test or oral rinse sample to determine if a person has a BRCA1 or BRCA2 mutation. Knowing the results may help patients and their healthcare professionals either prevent or delay the onset of cancer or detect it at an earlier, more treatable stage.
Medical management and BRACAnalysis ® testing
If the test confirms the presence of a BRCA1 or BRCA2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer, detect it at an earlier, more treatable stage or may even prevent it:
Increased surveillance for breast and/or ovarian cancer in mutation carriers;
Risk-reducing medications for mutation carriers; and/or
Prophylactic surgery for mutation carriers.